When was AUGUSTUS BioTarget founded?

AUGUSTUS BioTarget was founded in 2014.

Where is AUGUSTUS BioTarget located?

AUGUSTUS BioTarget is headquartered in North Myrtle Beach, United States.

Who is the current CEO of AUGUSTUS BioTarget?

Michael Scolaro of AUGUSTUS BioTarget. They have also founded 1 company.

Where does AUGUSTUS BioTarget rank among its competitors?

AUGUSTUS BioTarget ranks 2905th amongst 2265 active competitors, of which 550 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of AUGUSTUS BioTarget?

AUGUSTUS BioTarget's top competitors include Synthego, Liquidia and Sirnaomics. Among them, Antheia secured the most recent funding round in January, 2026.

AUGUSTUS BioTarget - 2026 Company Profile, Team & Competitors

AUGUSTUS BioTarget is a deadpooled company based in North Myrtle Beach (United States), founded in 2014 by Michael Scolaro. It operates as an Encapsulation-based drug delivery platform. The company has 2265 active competitors, including 550 funded and 363 that have exited. Its top competitors include companies like Synthego, Liquidia and Sirnaomics.

Company Details

Augustus BioTarget is a pharmaceutical company commercializing novel formulations of currently approved drugs using a proprietary drug delivery system licensed from Rodos BioTarget GmbH, called TargoSphere. The CLR-TargoSphere is a patented carbohydrate-labelled nanocarrier that recognizes carbohydrate receptor sites on the surface of APCs and delivers encapsulated agents into a pathway that evades intracellular endolysosomal enzymatic degradation. The company is currently developing CLR-TargoSphere encapsulated paclitaxel, CLR-TargoSphere encapsulated curcumin, and CLR-TargoSphere encapsulated gemcitabine with a goal to address colon cancer, chronic traumatic encephalopathy, Alzheimer's disease, and metastatic pancreatic adenocarcinoma.

Website: augustusbiotarget.com
Email ID: *****@AugustusBioTarget.com

Key Metrics

Founded Year

2014

Location

North Myrtle Beach, United States

Stage

Deadpooled

Ranked

2905^th among 3060 competitors

Similar Companies

Synthego & 3036 more

View AUGUSTUS BioTarget's full profile

AUGUSTUS BioTarget has not raised any funding rounds yet.

The founders of AUGUSTUS BioTarget is Michael Scolaro. Michael Scolaro is the CEO of AUGUSTUS BioTarget.

Here are the details of AUGUSTUS BioTarget's key team members:

Michael Scolaro: Founder & CEO of AUGUSTUS BioTarget.

View details of AUGUSTUS BioTarget's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AUGUSTUS BioTarget include Synthego, Liquidia and Sirnaomics. Here is the list of Top 10 competitors of AUGUSTUS BioTarget, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Gates & 18 others	67/100
3rd	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
4th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
5th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Sequoia Capital & 11 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
8th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
9th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
2905th	AUGUSTUS BioTarget 2014, North Myrtle Beach (United States), Deadpooled	Encapsulation-based drug delivery platform	-	-	15/100